Tarveda Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Tarveda Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013478
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tarveda Therapeutics Inc (Tarveda), formerly Blend Therapeutics Inc is a biopharmaceutical company that discovers and develops miniaturized novel biologic drug conjugates. The company develops targeted anti cancer medicines for advancing the treatment for solid tumors. Its pipeline prodicts includes its lead drug candidate, BTP-114, a novel, personalized cisplatin prodrug and BTP-277 and other novel drug conjugates from the company’s proprietary Pentarin platform. Tarveda offers PEN-221 designed to treat patients with neuroendocrine cancers and small cell lung cancer, and PEN-866 for the intracellular protein HSP90, is designed to treat patients with solid tumor cancers including colorectal cancer, small cell lung cancer and sarcoma. The company operates through other pharmaceutical companies to develop its proprietary Pentarins and new miniaturized biologic drug conjugates. Tarveda is headquartered in Watertown, Massachusetts, the US.

Tarveda Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Tarveda Therapeutics Raises USD30 Million in Series D Financing 11
Tarveda Therapeutics Raises Additional USD12.5 Million in Venture Financing 13
Blend Therapeutics Raises USD38 Million in Series C Financing 14
Blend Therapeutics Raises USD21 Million in Extended Series B Financing 15
Blend Therapeutics Raises US$0.9 Million In Venture Financing 17
Blend Therapeutics Raises US$21 Million In Series B Financing 18
Blend Therapeutics Secures US$2.8 Million In Series A Financing 20
Licensing Agreements 21
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 21
Blend Therapeutics Enters into Licensing Agreement with Biotech Company 22
Equity Offering 23
Placon Therapeutics Spin Out from Tarveda Therapeutics 23
Tarveda Therapeutics Inc – Key Competitors 24
Tarveda Therapeutics Inc – Key Employees 25
Tarveda Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Corporate Communications 27
Jun 19, 2017: Tarveda Therapeutics Appoints Biotech Business Veteran Michael A. Metzger to Board of Directors 27
Jan 27, 2016: Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer 28
Product News 29
11/22/2016: Tarveda to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 29
Clinical Trials 30
Sep 29, 2016: Tarveda to Present at North American Neuroendocrine Tumor Society (NANETS) Symposium 30
Other Significant Developments 31
Jan 04, 2017: Tarveda Therapeutics Provides Year-End Update and Outlines Milestones for 2017 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Tarveda Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Tarveda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Tarveda Therapeutics Raises USD30 Million in Series D Financing 11
Tarveda Therapeutics Raises Additional USD12.5 Million in Venture Financing 13
Blend Therapeutics Raises USD38 Million in Series C Financing 14
Blend Therapeutics Raises USD21 Million in Extended Series B Financing 15
Blend Therapeutics Raises US$0.9 Million In Venture Financing 17
Blend Therapeutics Raises US$21 Million In Series B Financing 18
Blend Therapeutics Secures US$2.8 Million In Series A Financing 20
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 21
Blend Therapeutics Enters into Licensing Agreement with Biotech Company 22
Placon Therapeutics Spin Out from Tarveda Therapeutics 23
Tarveda Therapeutics Inc, Key Competitors 24
Tarveda Therapeutics Inc, Key Employees 25

★海外企業調査レポート[Tarveda Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • James Fisher and Sons Plc (FSJ)-石油・ガス分野:企業M&A・提携分析
    Summary James Fisher and Sons plc (James Fisher) is a service provider that focuses on global marine industry and a specialist supplier of engineering services to the energy industry. The company provides comprehensive services such as design and engineering; inspection and monitoring; lifting and h …
  • Absa Bank Ltd:企業の戦略・SWOT・財務分析
    Absa Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Absa Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Carter Holt Harvey Ltd:企業の戦略・SWOT・財務情報
    Carter Holt Harvey Ltd - Strategy, SWOT and Corporate Finance Report Summary Carter Holt Harvey Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Texas Instruments Incorporated:企業の戦略・SWOT・財務情報
    Texas Instruments Incorporated - Strategy, SWOT and Corporate Finance Report Summary Texas Instruments Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hotel Croatia Cavtat:企業の戦略・SWOT・財務分析
    Hotel Croatia Cavtat - Strategy, SWOT and Corporate Finance Report Summary Hotel Croatia Cavtat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Helen of Troy Ltd:企業の戦略・SWOT・財務情報
    Helen of Troy Ltd - Strategy, SWOT and Corporate Finance Report Summary Helen of Troy Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Rakuten, Inc. (4755):企業の財務・戦略的SWOT分析
    Rakuten, Inc. (4755) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Guangzhou Wondfo Biotech Co Ltd (300482)-医療機器分野:企業M&A・提携分析
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that provides rapid diagnostic services. The company manufactures medical products and biochemical reagents. Its products include rapid test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo a …
  • Divi’s Laboratories Ltd (DIVISLAB):企業の財務・戦略的SWOT分析
    Divi's Laboratories Ltd (DIVISLAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Oltchim SA (OLT):企業の財務・戦略的SWOT分析
    Summary Oltchim SA (Oltchim) is a chemical company that manufactures and markets petrochemical products. The company offers inorganic, macro molecular and organic synthesis products. Its inorganic products include caustic soda, liquid chlorine, hydrochloric acid and sodium hypochlorite. Oltchim's ma …
  • Les Laboratoires Servier SAS:企業の戦略的SWOT分析
    Les Laboratoires Servier SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Alibaba Group Holding Limited:企業の戦略・SWOT・財務情報
    Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report Summary Alibaba Group Holding Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Solvang ASA (SOLV):企業の財務・戦略的SWOT分析
    Summary Solvang ASA (Solvang) is an oil and gas company that offers LPG and petrochemical gases transportation services. The company operates through its business areas such as semi-refrigerated or ethylene carriers, LGC, and panamax and VLGC. Its semi-refrigerated or ethylene carriers business area …
  • ITT Inc.:企業の戦略・SWOT・財務分析
    ITT Inc. - Strategy, SWOT and Corporate Finance Report Summary ITT Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Rubis SCA (RUI):石油・ガス:M&Aディール及び事業提携情報
    Summary Rubis SCA (Rubis) is an independent downstream company that carries out the storage, distribution and trading of bulk petroleum and chemical products. Its product portfolio includes fuel oil, liquefied petroleum gas (LPG), gasoline, diesel, home heating oil, chemical products, edible oils, m …
  • Mgm China Holdings Ltd:企業の戦略・SWOT・財務分析
    Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Mgm China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Pelican Rouge Group B.V.:企業の戦略・SWOT・財務情報
    Pelican Rouge Group B.V. - Strategy, SWOT and Corporate Finance Report Summary Pelican Rouge Group B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • First Solar Inc (FSLR)-エネルギー分野:企業M&A・提携分析
    Summary First Solar, Inc. (First Solar) is a provider of photovoltaic (PV) solar energy solutions. It designs, manufactures and sells PV solar modules with an advanced thin-film semiconductor technology; and also develops, designs, constructs and sells PV solar power systems. The company uses its Cd …
  • PT Perusahaan Gas Negara (Persero) Tbk (PGAS):石油・ガス:M&Aディール及び事業提携情報
    Summary PT Perusahaan Gas Negara (Persero) Tbk (PGN) is a downstream energy that transmits and distributes natural gas. The company plans, constructs and develops downstream natural gas businesses and carries out processing, transportation, storage and trading of natural gas. It produces, trades and …
  • IVERIC bio Inc (ISEE):企業の財務・戦略的SWOT分析
    Summary IVERIC bio Inc (IVERIC bio) formerly known as Ophthotech Corp, is a biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company’s products include Zimura, a complement inhibitor for stargardt di …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆